DJS-002
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 21, 2022
AbbVie acquires UK DJS…Securing candidates for idiopathic pulmonary fibrosis [Google translation]
(Hankyung)
- "AbbVie...acquire DJS Antibody, a UK unlisted antibody treatment developer....DJS' main drug candidate (pipeline) is 'DJS-002' for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF)."
Licensing / partnership • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1